Gonadotropin-releasing hormone agonist for ovulation trigger – OHSS prevention and use of modified luteal phase support for fresh embryo transfer

Abstract

The introduction of gonadotrophin-releasing hormone agonist (GnRHa) trigger greatly impacted modern IVF treatment. Patients at low risk of ovarian hyperstimulation syndrome (OHSS) development, undergoing fresh embryo transfer and GnRHa trigger can be offered a virtually OHSS-free treatment with non-inferior reproductive outcomes by using a modified luteal phase support in terms of small boluses of human chorionic gonadotrophin (hCG), daily recombinant luteinizing hormone LH (rLH) or GnRHa. In the OHSS risk patient, GnRHa trigger can safely be performed, followed by a ‘freeze-all’ policy with a minimal risk of OHSS development and high live birth rates in the subsequent frozen embryo transfer cycle. Importantly, GnRHa trigger opened the ‘black box’ of the luteal phase, promoting research in the most optimal steroid levels during the luteal phase. GnRHa trigger allows high-dose gonadotropin stimulation to achieve the optimal number of oocytes and embryos needed to ensure the highest chance of live birth. This review thoroughly discusses how the GnRHa trigger concept adds safety and efficacy to modern IVF in terms of OHSS prevention. Furthermore, the optimal luteal phase management after GnRHa trigger in fresh embryo transfer cycles is discussed.

Keywords:

• GnRHa trigger
• hCG
• IVF
• ovarian hyperstimulation syndrome
• ovulation trigger

Disclosure statement

Not related to this manuscript, T.H. received honoraria for lectures from Ferring, IBSA, Besins, and Merck. P.H. received unrestricted research grants from MSD, Merck, and Ferring as well as honoraria for lectures from MSD, Merck, Gedeon-Richter, Theramex, and IBSA. P.H. and T.H. are listed as inventors in an international patent application (PCT/UK2018/040882). The remaining authors have no disclosures.

Additional information

Notes on contributors

Juan Carlos Castillo

Juan Carlos Castillo is a senior consultant (MD PhD) at Instituto Bernabeu, Alicante, Spain.

Thor Haahr

Thor Haahr is a medical doctor and a PhD student at the Fertility Clinic Skive, and the Department of Clinical Medicine, Aarhus University, Denmark.

María Martínez-Moya

María Martínez-Moya is a consultant (MD) at Instituto Bernabeu, Alicante, Spain.

Peter Humaidan

Peter Humaidan is a senior consultant (MD, DMSc) and professor at the Fertility Clinic Skive, and the Department of Clinical Medicine, Aarhus University, Denmark.